Cabinet Carrel and BG2V have supported Anagenesis Biotechnologies in a new round of financing, the second since its creation in 2011
Carrel and BG2V advise Anagenesis Biotechnologies
Cabinet Carrel (Alexandra Carrel, partner, and Françoise Escoffier, of counsel) and BG2V (Stanislas Richoillez, partner, and Mathilde Périer, associate) have advised Anagenesis Biotechnologies in a new round of financing, the second since its creation in 2011.
Boehringer Ingelheim Venture Fund (BIVF) and Cap Innov’Est (CIE), a French inter-regional seed fund, already present in the capital of Anagenis, have invested 3 million euros in the company.
Anagenesis Biotechnologies (Anagenesis) is a biotech company developing therapies for the treatment of muscle degenerative diseases of genetic origin and related to aging.
The funds raised will be invested in the preclinical work necessary, in particular, to develop a drug to fight Duchenne muscular dystrophy (DMD) and should enable the company to take a new step in value creation by identifying the main cause of the disease.
Anagenesis, which has already received two private investments from AFM (French Muscular Dystrophy Association) to develop applications in the therapeutic field of skeletal muscle and from Cap Innov’Est, aims to become the world leader in the treatment of muscle diseases.
Cabinet Carrel advised Anagenesis on all IP and contractual aspects necessary to complete the transaction, confirming its expertise in the development of innovative companies.
BG2V, for its part, accompanied Anagenesis on all corporate aspects related to this fundraising, confirming the firm’s expertise in capital development operations and in supporting biotechnology companies.
Anagenesis’ legal counsel:
- Cabinet Carrel, with Alexandra Carrel, partner, and Françoise Escoffier, of counsel, for contractual and intellectual property aspects.
BG2V, with Stanislas Richoillez, partner, and Mathilde Périer, associate, for the corporate aspects,
Legal counsel to Boehringer Ingelheim Venture Fund:
- Mc Dermott, with Nicolas Lafont, partner, and Stephan de Groër, associate.